New support in the field of oncology
University of Geneva’s new agreement with Debiopharm boosts scientific innovation hub in the lemanic region of Switzerland through the IDEAL initiative.
The “Innovation Debiopharm Academia Léman” (IDEAL) initiative aims to financially and scientifically support researchers in the fields of oncology and antibiotics in the lemanic region in the cantons of Geneva, Vaud and Valais. After the signature last year of a first agreement with the Pharmaceutical Sciences Section of the Faculty of Sciences of the University of Geneva (UNIGE), a second IDEAL agreement was signed with the UNIGE Faculty of Medicine, to promote academic discoveries by accelerating the clinical development of new medicines.
This is the second partnership of this type signed between UNIGE and Debiopharm. In March 2021, the Pharmaceutical Sciences Section of the UNIGE Faculty of Sciences signed a first agreement with the IDEAL programme. Four research projects from the UNIGE have already received IDEAL funding and support.
“The agreement signed with Debiopharm guarantees us of course the freedom of research and dissemination of scientific discoveries”, added Mikaël Pittet, Full Professor, Chairman in Onco-immunology of the ISREC Foundation and Coordinator of the Translational Research Center in Onco-haematology of the UNIGE Faculty of Medicine.
“Currently, therapeutic advances are part of a model of cooperation between fundamental research, clinical care and the industrial sector. The expertise of all parties therefore complement each other to facilitate the advance in medicine. In addition, the IDEAL partnership is an opportunity for our young researchers to acquire an industrial perspective, which is an asset for their careers.”